Research-based clinical deployment of artificial intelligence algorithm for prostate MRI.
Authors
Affiliations (5)
Affiliations (5)
- National Institutes of Health, Bethesda, USA. [email protected].
- Nvidia (United States), Santa Clara, USA.
- National Institutes of Health, Bethesda, USA.
- Philips (United States), Andover, USA.
- National Institutes of Health, Bethesda, USA. [email protected].
Abstract
A critical limitation to deployment and utilization of Artificial Intelligence (AI) algorithms in radiology practice is the actual integration of algorithms directly into the clinical Picture Archiving and Communications Systems (PACS). Here, we sought to integrate an AI-based pipeline for prostate organ and intraprostatic lesion segmentation within a clinical PACS environment to enable point-of-care utilization under a prospective clinical trial scenario. A previously trained, publicly available AI model for segmentation of intra-prostatic findings on multiparametric Magnetic Resonance Imaging (mpMRI) was converted into a containerized environment compatible with MONAI Deploy Express. An inference server and dedicated clinical PACS workflow were established within our institution for evaluation of real-time use of the AI algorithm. PACS-based deployment was prospectively evaluated in two phases: first, a consecutive cohort of patients undergoing diagnostic imaging at our institution and second, a consecutive cohort of patients undergoing biopsy based on mpMRI findings. The AI pipeline was executed from within the PACS environment by the radiologist. AI findings were imported into clinical biopsy planning software for target definition. Metrics analyzing deployment success, timing, and detection performance were recorded and summarized. In phase one, clinical PACS deployment was successfully executed in 57/58 cases and were obtained within one minute of activation (median 33 s [range 21-50 s]). Comparison with expert radiologist annotation demonstrated stable model performance compared to independent validation studies. In phase 2, 40/40 cases were successfully executed via PACS deployment and results were imported for biopsy targeting. Cancer detection rates for prostate cancer were 82.1% for ROI targets detected by both AI and radiologist, 47.8% in targets proposed by AI and accepted by radiologist, and 33.3% in targets identified by the radiologist alone. Integration of novel AI algorithms requiring multi-parametric input into clinical PACS environment is feasible and model outputs can be used for downstream clinical tasks.